Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12

Showing 12 citing articles:

KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
At the nucleus of cancer: how the nuclear envelope controls tumor progression
Francesca Paganelli, Alessandro Poli, Serena Truocchio, et al.
MedComm (2025) Vol. 6, Iss. 2
Open Access
Emerging drugs for Epstein-Barr virus associated-diseases
Nassima Oumata, Qian Zhong, Yongmin Zhang, et al.
European Journal of Medicinal Chemistry (2025), pp. 117386-117386
Closed Access
A novel signature predicts prognosis in pancreatic cancer based on tumor membrane-associated genes
Zhaowei Ding, Jun Wu, Yongqing Ye, et al.
Heliyon (2025) Vol. 11, Iss. 4, pp. e42791-e42791
Open Access
Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib
Yannik Andrasch, Moses Munene Ireri, Jean-Charles Gander, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
Eszter Molnár, Marcell Baranyi, Krisztina Andrea Szigeti, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 1
The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition
Hetika Vora Patel, Alison Smith, Stacia Chan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib
Yannik Andrasch, Moses Munene Ireri, Ann-Engelke Sabrina Timm, et al.
Research Square (Research Square) (2024)
Open Access
Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma
Sára Eszter Surguta, Marcell Baranyi, Laura Svajda, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Page 1

Scroll to top